Amphastar Pharmaceuticals
AMPH
269 hedge funds and large institutions have $1.37B invested in Amphastar Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 38 funds opening new positions, 100 increasing their positions, 100 reducing their positions, and 37 closing their positions.
15% more call options, than puts
Call options by funds: $1.29M | Put options by funds: $1.12M
3% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 37
0.5% more ownership
Funds ownership: 69.78% → 70.27% (+0.5%)
0% more repeat investments, than reductions
Existing positions increased: 100 | Existing positions reduced: 100
0% less funds holding
Funds holding: 270 → 269 (-1)
7% less capital invested
Capital invested by funds: $1.47B → $1.37B (-$98.5M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TD Asset Management
Toronto,
Ontario, Canada
|
+$28.2M |
| 2 |
Millennium Management
New York
|
+$14M |
| 3 |
EIP
Epoch Investment Partners
New York
|
+$11.6M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$9.41M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$8.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OAM
Oberweis Asset Management
Lisle,
Illinois
|
-$11.7M |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$6.89M |
| 3 |
LSV Asset Management
Chicago,
Illinois
|
-$5.98M |
| 4 |
BlackRock
New York
|
-$5.66M |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$5.48M |
AMPH Hedge Fund Activity: Q2 2024 in Review
269 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in Amphastar Pharmaceuticals (AMPH) for Q2 2024, worth a combined $1.37B — down 6.7% from $1.47B a quarter earlier.
Buyers outnumbered sellers: 38 funds opened new AMPH positions and 37 closed out — a net gain of 1 holder — while 100 added to existing stakes and 100 trimmed.
The largest buyer was TD Asset Management, adding an estimated $28.2M. The largest seller was Oberweis Asset Management, cutting an estimated $11.7M.
- 269 institutional investors held Amphastar Pharmaceuticals (AMPH) as of Q2 2024, down from 270 in Q1 2024.
- Funds reported $1.37B of Amphastar Pharmaceuticals stock for Q2 2024, down 6.7% quarter-over-quarter.
- 38 funds opened new Amphastar Pharmaceuticals positions in Q2 2024 and 37 closed out, a net change of +1 holder.
- The largest Amphastar Pharmaceuticals buyer in Q2 2024 was TD Asset Management, an estimated $28.2M added.
- The largest Amphastar Pharmaceuticals seller in Q2 2024 was Oberweis Asset Management, an estimated $11.7M sold.
Based on aggregated 13F filings for Q2 2024.